Form 8-K - Current report:
SEC Accession No. 0001682852-24-000031
Filing Date
2024-05-09
Accepted
2024-05-08 17:58:33
Documents
16
Period of Report
2024-05-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20240506.htm   iXBRL 8-K 59310
2 EX-3.1 exhibit3158248-k.htm EX-3.1 40308
3 EX-3.2 exhibit325820248-k.htm EX-3.2 205931
  Complete submission text file 0001682852-24-000031.txt   520826

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20240506.xsd EX-101.SCH 2161
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrna-20240506_def.xml EX-101.DEF 15273
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20240506_lab.xml EX-101.LAB 26946
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20240506_pre.xml EX-101.PRE 15975
19 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20240506_htm.xml XML 2806
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 24927770
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)